WEKO3
-
RootNode
アイテム
Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療（IMRT）の中期治療成績
http://hdl.handle.net/10422/1711
http://hdl.handle.net/10422/1711e8255f7c-8af6-41d8-9bcd-521eef1b9bd2
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
jsums2601p006.pdf (476.8 kB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2016-04-12 | |||||
| タイトル | ||||||
| タイトル | Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療（IMRT）の中期治療成績 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| その他のタイトル | ||||||
| その他のタイトル | Results of IMRT following neoadjuvant hormone therapy for clinical stage C prostate cancer | |||||
| タイトル（ヨミ） | ||||||
| その他のタイトル | Stage C ゼンリツセンガン ニ タイスル ナイブンピツ ホルモン リョウホウ ヘイヨウ キョウド ヘンチョウ ホウシャセン チリョウ IMRT ノ チュウキ チリョウ セイセキ | |||||
| 著者 |
河野, 直明
× 河野, 直明× 邵, 啓全× 津川, 拓也× 村田, 喜代史× 野間, 和夫× 本多, 恵理子× 橋本, 惠次× 近藤, 康雄× Ushida, Hiroshi× 岡本, 圭生× 岡田, 裕作 |
|||||
| 内容記述 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | We report the 5-year prostate-specific antigen (PSA) relapse-free survival outcome and incidence of toxicity forpatients with clinically Stage C prostate cancer treated with intensity-modulated radiation therapy (IMRT) in our institute. Atotal of 35 patients with Stage C prostate cancer were treated with IMRT between July 2003 and November 2007. All patientswere treated to a dose of 74Gy prescribed to the planning target volume and received neoadjuvant hormone therapy. Themedian age was 71 years (range: 50 to 80 years). 3 patients (8.6%) had Gleason scores ＜or=6, 14 patients (40.0%) hadGleason scores 7, 18 patients (51.4%) had Gleason scores >or=8. The median pretreatment PSA level was 28.0 ng/mL (range:5.1 to 160.0 ng/mL). Patients were characterized as having high risk disease if their pretreatment PSA level was >20ng/ml andGleason score >or=8. PSA relapse-free survival rate were calculated and toxicity data were scored according to the CommonTerminology Criteria for Adverse Events Version 3.0. The median follow-up time was 58 months (range 7 to 84). 11 patients(31.4%) developed a PSA relapse, and the 5-year PSA relapse-free survival rate was 66.3%. The 5-year PSA relapse-freesurvival rates for high risk patients and others were 39.2% and 85.7%, respectively (p=0.0098). The likelihood of acute grade 2urinary and rectal toxicity was 14.2% and 11.4%. No grade 2 late complications have been observed. These results indicatedthat 74Gy IMRT is well tolerated and is associated with good PSA relapse-free survival outcomes in patients with Stage Cprostate cancer, especially non-high risk patient. | |||||
| 書誌情報 |
滋賀医科大学雑誌 巻 26, 号 1, p. 6-12, 発行日 2012-11-07 |
|||||
| 出版者 | ||||||
| 出版者 | 滋賀医科大学雑誌編集委員会 | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Departmental Bulletin Paper | |||||
